Roche announced that detailed results from the evERA Breast Cancer study, showing investigational giredestrant in combination with everolimus significantly improved progression-free survival (PFS) ...

Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy p ...

Danish drugmaker Lundbeck explores acquisition of Xeris Biopharma, sending Xeris shares to 2019 highs as markets react to the ...

From September 27 to November 25, 2026, Mars in Leo fires up courage, pride and creativity. Mars-Jupiter conjunction on ...

Hello everyone. I am Akiyama, a personal trainer.In the previous article, we organized the "three major principles and five ...

Background Patients with systemic lupus erythematosus (SLE) carry a substantial comorbidity load associated with worse prognosis, yet most evidence pertains to long-standing disease. How comorbidities ...

Novo Nordisk (NVO) shares dropped 9% Monday after revealing 2030 growth targets aligned with pharma peers and plans for five new blockbuster drug launches.

Public comments are due by 11:59 pm ET on September 24, 2026. In response to a U.S. Environmental Protection Agency’s (EPA) public comment period on the active ingredient glyphosate used in weed ...

Perine (knee) was listed as a non-participant at the Bengals' practice Thursday. Advice: Perine was added to the injury report with an apparent knee injury after opening the week without a listed ...

Chase Brown's gained 78 total yards during Week 1 on a modest 3.7 per touch, and the Bengals' No. 1 back draws a tough Week 2 matchup against a Texans defense that contained the Bills' James Cook to ...

NEW DELHI: The government should undertake a comprehensive review of the functioning of Panchayati Raj Institutions (PRIs) and prepare a roadmap for the “next generation of panchayat reforms” to ...

Agentic AI is taking root across health systems faster than the governance structures built to contain it. The technology questions, for the most part, are settled. What remains unresolved is whether ...